Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (361-370 of 440) with videos related to

Pageof 44
Sort By:
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trialSaad Zafar Usmani, Fredrik Schjesvold, Albert Oriol, et al.
The New England Journal of Medicine|June 17, 2005
Bortezomib or high-dose dexamethasone for relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2022
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With MyelomaAjay K Nooka, Uma Shanmugasundaram, Narayana Cheedarla, et al.
British Journal of Haematology|June 28, 2017
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trialJesús F San-Miguel, Vania T M Hungria, Sung-Soo Yoon, et al.
Blood|December 18, 2024
Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesisRemya Nair, An H Vu, Abigail K Freer, et al.
The Lancet. Oncology|February 15, 2014
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient dataAntonio Palumbo, Sara Bringhen, Shaji K Kumar, et al.
Cell|May 5, 2022
Systematic discovery of mutation-directed neo-protein-protein interactions in cancerXiulei Mo, Qiankun Niu, Andrey A Ivanov, et al.
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
Nucleic Acids Research|May 23, 2024
Transposon DNA sequences facilitate the tissue-specific gene transfer of circulating tumor DNA between human cellsMunevver Cinar, Lourdes Martinez-Medina, Pavan K Puvvula, et al.
Blood|June 30, 2009
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimensShaji Kumar, Sergio Giralt, Edward A Stadtmauer, et al.
Pageof 44

Showing results (361-370 of 440) with videos related to

Sort By:
Pageof 44
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trialSaad Zafar Usmani, Fredrik Schjesvold, Albert Oriol, et al.
The New England Journal of Medicine|June 17, 2005
Bortezomib or high-dose dexamethasone for relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2022
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With MyelomaAjay K Nooka, Uma Shanmugasundaram, Narayana Cheedarla, et al.
British Journal of Haematology|June 28, 2017
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trialJesús F San-Miguel, Vania T M Hungria, Sung-Soo Yoon, et al.
Blood|December 18, 2024
Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesisRemya Nair, An H Vu, Abigail K Freer, et al.
The Lancet. Oncology|February 15, 2014
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient dataAntonio Palumbo, Sara Bringhen, Shaji K Kumar, et al.
Cell|May 5, 2022
Systematic discovery of mutation-directed neo-protein-protein interactions in cancerXiulei Mo, Qiankun Niu, Andrey A Ivanov, et al.
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
Nucleic Acids Research|May 23, 2024
Transposon DNA sequences facilitate the tissue-specific gene transfer of circulating tumor DNA between human cellsMunevver Cinar, Lourdes Martinez-Medina, Pavan K Puvvula, et al.
Blood|June 30, 2009
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimensShaji Kumar, Sergio Giralt, Edward A Stadtmauer, et al.
Pageof 44